Article Details
Retrieved on: 2025-06-10 20:55:01
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Merck KGaA's filing follows FDA approval of a competing oral TGCT therapy, vimseltinib, and aligns with its broader innovation strategy via Peregrine ...
Article found on: www.pharmtech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here